Stem cell injections, platelet rich plasma and ivermectin do big business despite dubious or no evidence supporting their use in rheumatology. However, far from being a recent development, this type ...

Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative ...

New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa ...

First Quarter 2025 Financial Results: G&A Expenses: For the quarter ended March 31, 2025, general and administrative (G&A) expenses were $4.6 million, compared to $5.4 million for the same period in ...

IntroductionThe global mesenchymal stem cells market is witnessing a significant transformation as advancements in ...

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on ...

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative ...

People with type 2 diabetes don’t make an adequate amount of insulin to manage their blood sugar. Stem cell therapy may potentially allow people with type 2 diabetes to start producing more insulin ...